In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

Immune checkpoint inhibitors (ICIs), a major type of cancer immunotherapy, don't do much for hospitalized cancer patients, ...

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...